| Private Placement / Financing Transactions
OpenEvidence: The company raised $250 million of Series D venture funding in a deal led by Thrive Capital and DST Global on January 21, 2026, putting the company’s pre-money valuation at $11.75 billion. Nvidia, Mayo Clinic Ventures, Kleiner Perkins, and GV also participated in the round. The company is a developer of an AI copilot for doctors that helps them make high-stakes decisions at the point of care.
Mendra: The company raised $82 million of Series A venture funding in a deal led by OrbiMed, 8VC and 5AM Ventures on January 21, 2026. Lux Capital and Wing Venture Capital also participated in the round. The company is a developer of an AI-native rare disease therapeutic development platform acquiring and commercializing de-risked assets using AI for patient identification, clinical trial enrollment optimization, and global market access acceleration.
PAQ Therapeutics: The company raised $77 million of Series B venture funding in a deal led by MRL Ventures Fund and Bayland Capital on January 22, 2026. LAV Fund, Johnson & Johnson JJDC, Sherpa Healthcare Partners, BioTrack Capital, Johnson & Johnson Innovation – JLABS and other undisclosed investors also participated in the round. The company is a developer of autophagy-modulating therapeutics for disease treatment and health restoration.
Orbem: The company raised EUR 55.5 million of Series B venture funding in a deal led by Innovation Industries (Amsterdam) on January 20, 2026. Possible Ventures, The Venture Collective, 83North, Supernova Invest and General Catalyst also participated in the round. The company is a developer of an AI-enabled magnetic resonance imaging platform generating non-invasive biological insights.
Exciva: The company raised EUR 51 million of Series B venture funding in a deal led by Gimv and EQT Life Sciences on January 20, 2026. LBBW Venture Capital, Andera Partners, Fountain Healthcare Partners, LifeArc, CARMA FUND Management and Modi Ventures also participated in the round. The company is a developer of antitussive medications addressing neurological and psychological aspects of chronic cough.
Think Bioscience: The company raised $54.8 million of Series A funding in a deal led by Regeneron Ventures, Innovation Endeavors and Janus Henderson Investors on January 20, 2026, putting the company’s pre-money valuation at $85.18 million. CU Healthcare Innovation Fund, CE-Ventures, T.A. Springer, MBX Capital, YK Bioventures, AV8 Ventures, Buff Gold Ventures and other undisclosed investors also participated in the round. The company is a developer of synthetic biology systems guiding the design and assembly of therapeutic molecules.
TwoStep Therapeutics: The company raised $21.1 million of Series A venture funding from 2048 Ventures, NFX and other undisclosed investors on January 20, 2026, putting the company’s pre-money valuation at $43.4 million. The company is a developer of novel tumor-targeting therapeutics for solid tumors.
Aviwell: The company raised GBP 11 million of Series A venture funding in a deal led by Hatch Blue on January 23, 2026. SWEN Capital Partners, Blast.Club, Elaia Partners, and MFS Investment Management also participated in the round. The company is a developer of a microbiota-based AI/ML discovery platform operating at the convergence of digital and life sciences.
BrightInsight: The company raised $13 million of venture funding from Mayo Clinic, New Leaf Venture, and Eclipse Ventures on January 20, 2026. Insight Partners, General Catalyst, and other undisclosed investors also participated in the round. The company is a developer of a digital health platform optimizing regulated drugs, devices, and software through integrated data.
Eolas Medical: The company raised GBP 8.9 million through a combination of debt and Series A venture funding on January 19, 2026, putting the company’s pre-money valuation at GBP 21.05 million. GBP 7.643297 million of Series A was led by Acton Capital with participation from Scalex Investments, Whiterock Capital, Ascension, Samaipata, Kindred Capital, and Portfolio Ventures. The company is an operator of a health-tech platform providing AI-powered, SaaS-based knowledge management services.
RobotDreams: The company is in the process of raising EUR 10 million of venture funding as of January 19, 2026. The company is a developer of an AI-based diagnostic software for hematological data analysis identifying physiological conditions in clinical settings.
Sense Neuro Diagnostics: The company is in the process of raising $9 million of Series B venture funding in a deal led by QCA First Funds on January 19, 2026, putting the company’s pre-money valuation at $23 million. Bearcat Ventures, UC Ventures and Alloy Growth Lab is also participating in the round. It plans to close the round by April 30, 2026. The company is a developer of noninvasive radiofrequency sensors designed to detect major changes in the brain.
QV Bioelectronics: The company raised GBP 4.5 million of venture funding in a deal led by Praetura Ventures and PraeSeed on January 21, 2026. Empirical Ventures, Innovate UK and National Institute for Health and Care Research also participated in the round. The company is a developer of an implanted electric field therapy device designed to treat brain tumors.
Cantai Therapeutics: The company raised $3.5 million of venture funding from undisclosed investors on January 21, 2026. The company is a developer of next-generation bispecific antibodies for autoimmune diseases.
|
